1994
DOI: 10.1148/radiographics.14.1.8128041
|View full text |Cite
|
Sign up to set email alerts
|

Methionine PET for follow-up of radiation therapy of primary lymphoma of the brain.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

1
42
1

Year Published

2008
2008
2019
2019

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 64 publications
(44 citation statements)
references
References 0 publications
1
42
1
Order By: Relevance
“…54 More recently, superparamagnetic contrast agents, (eg, iron oxide nanoparticles) have become available. 55 MR imaging with iron oxide nanoparticles may help to distinguish ma- Characteristic intensity time curve related to leakage of contrast into the interstitial space 41 Differentiation of CNS lymphoma and malignant glioma/ metastases Assessment of microvascular tumor permeability relevant for diagnosis, prognostication, and therapy MR spectroscopy Elevated lipid peaks and high Cho/Cr ratios 29,[42][43][44]59 Differentiation of CNS lymphoma and some gliomas and CNS lymphomas and toxoplasmosis/PML in AIDS patients High-resolution SWI Blood products and calcifications are rare findings 14,27 Differentiation of CNS lymphoma and high-grade gliomas MRI with new contrast agents MRI with iron oxide nanoparticles: lesions enhance less than with gadolinium 56 Differentiation of CNS lymphoma and MS Metabolic imaging PET FDG-PET, methionine PET: hypermetabolic lesions with increased uptake of FDG or methionine 25,60,62 Differentiation of CNS lymphoma and gliomas/metastases/ meningiomas Early evaluation of therapeutic response SPECT/SPET Hypermetabolic lesions with high N-isopropyl iodoamphetamine or thallium-201 uptake 9,63,64 Differentiation of AIDS-related CNS lymphoma and infectious intracranial lesions lignant neoplasms from multiple sclerosis 56 ; however, to our knowledge, the potential role of this technique in the diagnosis of CNS lymphoma has not yet been defined.…”
mentioning
confidence: 99%
See 3 more Smart Citations
“…54 More recently, superparamagnetic contrast agents, (eg, iron oxide nanoparticles) have become available. 55 MR imaging with iron oxide nanoparticles may help to distinguish ma- Characteristic intensity time curve related to leakage of contrast into the interstitial space 41 Differentiation of CNS lymphoma and malignant glioma/ metastases Assessment of microvascular tumor permeability relevant for diagnosis, prognostication, and therapy MR spectroscopy Elevated lipid peaks and high Cho/Cr ratios 29,[42][43][44]59 Differentiation of CNS lymphoma and some gliomas and CNS lymphomas and toxoplasmosis/PML in AIDS patients High-resolution SWI Blood products and calcifications are rare findings 14,27 Differentiation of CNS lymphoma and high-grade gliomas MRI with new contrast agents MRI with iron oxide nanoparticles: lesions enhance less than with gadolinium 56 Differentiation of CNS lymphoma and MS Metabolic imaging PET FDG-PET, methionine PET: hypermetabolic lesions with increased uptake of FDG or methionine 25,60,62 Differentiation of CNS lymphoma and gliomas/metastases/ meningiomas Early evaluation of therapeutic response SPECT/SPET Hypermetabolic lesions with high N-isopropyl iodoamphetamine or thallium-201 uptake 9,63,64 Differentiation of AIDS-related CNS lymphoma and infectious intracranial lesions lignant neoplasms from multiple sclerosis 56 ; however, to our knowledge, the potential role of this technique in the diagnosis of CNS lymphoma has not yet been defined.…”
mentioning
confidence: 99%
“…61 PET performed with 11 C-methionine (methionine PET) shows very high uptakes in CNS lymphomas, which corresponds to the enhancing portion on CT/MR imaging, and the area of increased uptake is often larger than the enhancing lesions (Fig 7). 62 This larger area of methionine uptake reflects tumor infiltration beyond the enhancing portion seen on MR imaging and CT. 62 The size and degree of methionine accumulation in the tumor tissue decrease following radiation therapy. 62 Thus, methionine PET may provide a more accurate delineation of tumor volume for the evaluation of the therapeutic effect of radiation therapy as well as for the detection of residual or recurrent tumor after treatment.…”
mentioning
confidence: 99%
See 2 more Smart Citations
“…Thus, we sought to characterize the activity of LAT1 in pediatric and young adult patients with lymphoma, assess the biodistribution of the tracer in tumor sites, and compare with 18 F-FDG PET/CT used for staging and response (2). 18 F-FDG is a valuable radiopharmaceutical tracer to stage, monitor response to therapy, and detect relapsed disease in lymphomas occurring in both adults and children. Nevertheless, 18 F-FDG has limitations to its use (3).…”
mentioning
confidence: 99%